The natural history of hepatitis C infection acquired through injection drug use: Meta-analysis and meta-regression

Journal of Hepatology

Volumn 53, Issue 2, 2010, Pages 245-251

  John Baptiste, Ava ^a,b,c   Krahn, Murray ^a,b,c   Heathcote, Jenny ^c,d   Laporte, Audery ^a,d   Tomlinson, George ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cirrhosis; Fibrosis progression; Injection drug use; Meta analysis; Meta regression; Risk factors

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; DISEASE COURSE; DISEASE DURATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIVER CIRRHOSIS; MALE; META ANALYSIS; MIXED INFECTION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; COMPLICATION; DRINKING BEHAVIOR; HEPACIVIRUS; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK FACTOR; SUBSTANCE ABUSE;

ADULT; ALCOHOL DRINKING; DISEASE PROGRESSION; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 77955305804     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.03.015     Document Type: Article

References (34)

1. R Development Core Team R: a language and environment for statistical computing 2009 R Foundation for Statistical Computing Vienna, Austria ISBN 3-900051-07-0. Available from: http://www.R-project.org
2. O.M. Adeyemi, D. Jensen, B. Attar, R. Ghaoui, M. Gallagher, and D. Wolen Hepatitis C treatment eligibility in an urban population with and without HIV coinfection AIDS Patient Care STDs 18 2004 239 245
3. G.L. Armstrong, A. Wasley, E.P. Simard, G.M. McQuillan, W.L. Kuhnert, and M.J. Alter The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 144 2006 705 714 [See comment: Summary for patients in Ann Intern Med 2006;144:I20; PMID: 16702583]
4. P. Bacchetti, P.C. Tien, E.C. Seaberg, T.R. O'Brien, M.H. Augenbraun, and A.H. Kral Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression BMC Infect Dis 7 2007 145
5. N. Brau, M. Salvatore, C.F. Rios-Bedoya, A. Fernandez-Carbia, F. Paronetto, and J.F. Rodriguez-Orengo Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy J Hepatol 44 2006 47 55
6. S.P. Brooks, and A. Gelman General methods for monitoring convergence of iterative simulations J Comput Graph Stat 7 1998 434 455
7. A. Bruandet, D. Lucidarme, A. Decoster, D. Ilef, J. Harbonnier, and C. Jacob Incidence and risk factors of HCV infection in a cohort of intravenous drug users in the North and East of France Rev Epidemiol Sante Publique 54 2006 1S15 11S22 [in French]
8. D.R. Cox Analysis of survival data 1984 Chapman and Hall New York
9. N. Crofts, D. Jolley, J. Kaldor, I. van Beek, and A. Wodak Epidemiology of hepatitis C virus infection among injecting drug users in Australia J Epidemiol Commun Health 51 1997 692 697 (Pubitemid 28014247)
10. M.H. De Groot Optimal statistical decisions 1970 McGraw-Hill New York
11. R. DerSimonian Meta-analysis in the design and monitoring of clinical trials Stat Med 15 1996 1237 1248 discussion 1249-1252
12. A.M. Di Bisceglie Hepatitis C Lancet 351 1998 351 355
13. A.M. Di Bisceglie Natural history of hepatitis C: its impact on clinical management Hepatology 31 2000 1014 1018
14. A.J. Freeman, G.J. Dore, M.G. Law, M. Thorpe, J. Von Overbeck, and A.R. Lloyd Estimating progression to cirrhosis in chronic hepatitis C virus infection Hepatology 34 2001 809 816
15. B. Fu, B.D. Tom, T. Delahooke, G.J. Alexander, and S.M. Bird Event-biased referral can distort estimation of hepatitis C virus progression rate to cirrhosis, and of prognostic influences J Clin Epidemiol 60 2007 1140 1148
16. J. Grebely, J.D. Raffa, C. Lai, M. Krajden, T. Kerr, and B. Fischer Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents J Viral Hepat 16 2009 352 358
17. S. Greenland, and H. Morgenstern Ecological bias, confounding, and effect modification Int J Epidemiol 18 1989 269 274
18. A. John-Baptiste, M. Varenbut, M. Lingley, T. Nedd-Roderique, D. Teplin, and G. Tomlinson Treatment of hepatitis C infection for current or former substance abusers in a community setting J Viral Hepat 16 2009 557 567
19. A. Judd, M. Hickman, S. Jones, T. McDonald, J.V. Parry, and G.V. Stimson Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study BMJ 330 2005 24 25
20. P.C. Lambert, A.J. Sutton, K.R. Abrams, and D.R. Jones A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis J Clin Epidemiol 55 2002 86 94
21. D.J. Lunn, A. Thomas, N. Best, and D. Spiegelhalter WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility Stat Comput 10 2000 325 337
22. C.L. Miller, P.M. Spittal, J.C. Frankish, K. Li, M.T. Schechter, and E. Wood HIV and hepatitis C outbreaks among high-risk youth in Vancouver demands a public health response Can J Public Health 96 2005 107 108
23. T. Poynard, P. Bedossa, and P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Lancet 349 1997 825 832
24. A.J. Rodger, S. Roberts, A. Lanigan, S. Bowden, T. Brown, and N. Crofts Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975 Hepatology 32 2000 582 587
25. M. Schaefer, A. Heinz, and M. Backmund Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 99 2004 1167 1175
26. A.A. Shaheen, and R.P. Myers Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review Hepatology 46 2007 912 921
27. A.F.M. Smith, and G.O. Roberts Bayesian computation via the Gibbs sampler and related Markov-chain Monte-Carlo methods J R Stat Soc Ser B Methodol 55 1993 3 23
28. D.J. Spiegelhalter, J.P. Myles, D.R. Jones, and K.R. Abrams Methods in health service research. An introduction to bayesian methods in health technology assessment BMJ 319 1999 508 512
29. S.A. Strathdee, D.M. Patrick, S.L. Currie, P.G. Cornelisse, M.L. Rekart, and J.S. Montaner Needle exchange is not enough: lessons from the Vancouver injecting drug use study AIDS 11 1997 F59 F65
30. H.H. Thein, Q. Yi, G.J. Dore, and M.D. Krahn Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression Hepatology 48 2008 418 431
31. H.H. Thein, Q. Yi, G.J. Dore, and M.D. Krahn Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis AIDS 22 2008 1979 1991
32. A. Thomas, B. O'Hara, U. Ligges, and S. Sturtz Making BUGS open R News 6 2006 12 17
33. S.A. Villano, D. Vlahov, K.E. Nelson, C.M. Lyles, S. Cohn, and D.L. Thomas Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland J Clin Microbiol 35 1997 3274 3277
34. Q. Yi, P.P. Wang, and M. Krahn Improving the accuracy of long-term prognostic estimates in hepatitis C virus infection J Viral Hepat 11 2004 166 174